Morise M - Search Results

1

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.

Tanaka I, Morise M. Tanaka I, et al. Among authors: morise m. Int J Mol Sci. 2021 Dec 27;23(1):245. doi: 10.3390/ijms23010245. Int J Mol Sci. 2021. PMID: 35008669 Free PMC article. Review.

2

Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?

Kato T, Morise M, Ando M, Kojima E, Ogasawara T, Suzuki R, Shindoh J, Matsumoto M, Sugino Y, Ogawa M, Nozaki Y, Hase T, Kondo M, Saito H, Hasegawa Y. Kato T, et al. Among authors: morise m. J Cancer Res Clin Oncol. 2016 Jul;142(7):1629-40. doi: 10.1007/s00432-016-2170-z. Epub 2016 May 11. J Cancer Res Clin Oncol. 2016. PMID: 27166967

3

A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.

Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y. Tanaka I, et al. Among authors: morise m. Cancer Chemother Pharmacol. 2018 Feb;81(2):339-345. doi: 10.1007/s00280-017-3497-0. Epub 2017 Dec 12. Cancer Chemother Pharmacol. 2018. PMID: 29234921 Clinical Trial.

4

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy.

Omote N, Hashimoto N, Morise M, Sakamoto K, Miyazaki S, Ando A, Nakahara Y, Hasegawa Y. Omote N, et al. Among authors: morise m. Int J Chron Obstruct Pulmon Dis. 2017 Dec 11;12:3541-3547. doi: 10.2147/COPD.S149456. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29270008 Free PMC article.

5

eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer.

Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. Tanaka I, et al. Among authors: morise m. Cancer Sci. 2018 Jun;109(6):1843-1852. doi: 10.1111/cas.13602. Epub 2018 May 25. Cancer Sci. 2018. PMID: 29624814 Free PMC article.

6

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.

Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y. Sato M, et al. Among authors: morise m. Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10. Intern Med. 2018. PMID: 30101911 Free PMC article.

7

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.

Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S, Goto D, Miyazawa A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Tanaka I, et al. Among authors: morise m. Lung Cancer. 2019 Jan;127:169-171. doi: 10.1016/j.lungcan.2018.11.018. Epub 2018 Nov 14. Lung Cancer. 2019. PMID: 30477806 No abstract available.

8

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.

Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. Akamatsu H, et al. Among authors: morise m. Int J Clin Oncol. 2019 Jul;24(7):731-770. doi: 10.1007/s10147-019-01431-z. Epub 2019 May 2. Int J Clin Oncol. 2019. PMID: 31049758 Free PMC article.

9

Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.

Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Fukihara J, et al. Among authors: morise m. Clin Lung Cancer. 2019 Nov;20(6):442-450.e4. doi: 10.1016/j.cllc.2019.07.006. Epub 2019 Aug 1. Clin Lung Cancer. 2019. PMID: 31446020

10

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.

Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: morise m. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

101 results

Search Page